CD44 and head and neck squamous cell carcinoma: In addition, xenograft tumor growth assay revealed that CD44 knockdown inhibited in vivo tumorigenesis and metastasis of HCT116‐CSCs, which is in agreement with the reports seen in breast cancer49, 50 and head and neck squamous cell carcinoma.51